Format

Send to

Choose Destination
Prostate. 2017 Oct;77(14):1401-1407. doi: 10.1002/pros.23401. Epub 2017 Aug 29.

A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.

Author information

1
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
2
Department of Nuclear Medicine and Radiology, Radboud University Medical Center, Nijmegen, The Netherlands.
3
Department of Mathematical Modeling, Statistics and Bio-Informatics, Ghent University, Ghent, Belgium.
4
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Abstract

BACKGROUND:

Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non-invasive techniques for the detection of clinically significant disease, leading to a reduction of over-diagnosis and over-treatment. The aim of this study was to determine the association between a novel urinary biomarker-based risk score (SelectMDx), multiparametric MRI (mpMRI) outcomes, and biopsy results for PCa detection.

METHODS:

This retrospective observational study used data from the validation study of the SelectMDx score, in which urine was collected after digital rectal examination from men undergoing prostate biopsies. A subset of these patients also underwent a mpMRI scan of the prostate. The indications for performing mpMRI were based on persistent clinical suspicion of PCa or local staging after PCa was found upon biopsy. All mpMRI images were centrally reviewed in 2016 by an experienced radiologist blinded for the urine test results and biopsy outcome. The PI-RADS version 2 was used.

RESULTS:

In total, 172 patients were included for analysis. Hundred (58%) patients had PCa detected upon prostate biopsy, of which 52 (52%) had high-grade disease correlated with a significantly higher SelectMDx score (P < 0.01). The median SelectMDx score was significantly higher in patients with a suspicious significant lesion on mpMRI compared to no suspicion of significant PCa (P < 0.01). For the prediction of mpMRI outcome, the area-under-the-curve of SelectMDx was 0.83 compared to 0.66 for PSA and 0.65 for PCA3. There was a positive association between SelectMDx score and the final PI-RADS grade. There was a statistically significant difference in SelectMDx score between PI-RADS 3 and 4 (P < 0.01) and between PI-RADS 4 and 5 (P < 0.01).

CONCLUSIONS:

The novel urinary biomarker-based SelectMDx score is a promising tool in PCa detection. This study showed promising results regarding the correlation between the SelectMDx score and mpMRI outcomes, outperforming PCA3. Our results suggest that this risk score could guide clinicians in identifying patients at risk for significant PCa and selecting patients for further radiological diagnostics to reduce unnecessary procedures.

KEYWORDS:

SelectMDx score; multiparametric MRI; prostate cancer

PMID:
28853167
DOI:
10.1002/pros.23401
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center